Document:

Amendment to Development and License Agreement

 Exhibit 10.6 
  
 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Commission. The omitted portions,
marked by “*”, have been separately filed with the Commission. 
  
 AMENDMENT TO THE DEVELOPMENT AND LICENSE AGREEMENT 
  
 This AMENDMENT TO THE DEVELOPMENT AND LICENSE AGREEMENT (“Amendment”) is executed on this 12th day of July 2004 to be effective the 5th day of January 2004, by and between Trimeris, Inc. (“Trimeris”), and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively, “Roche”). 
  
 WHEREAS, Trimeris and Roche have previously entered into a Development and
License Agreement (including its Appendices) dated as of the 1st day of July 1999, by and between Trimeris and Roche
(the “Agreement”), which sets forth the Parties’ rights, duties and obligations under the Agreement; and 
  
 WHEREAS, Section 5.2 and Appendix D of the Agreement prohibit Roche from unilaterally adopting a marketing budget that calls for spending more than the
limits set forth in Appendix D; and 
  
 NOW, THEREFORE, in
consideration for the foregoing promises and for good and valuable consideration, the receipt and sufficiency which is hereby acknowledged, the Parties hereby agree as follows: 
  

	 	1.	For the purposes of this Amendment, Adjusted Gross Sales (“AGS”) shall refer to the Adjusted Gross Sales of FUZEON only. 

  

	 	2.	Paragraph 3(e) shall be added to Appendix D as follows: 

  
 Notwithstanding paragraph 3(a) above, Roche shall be permitted to adopt a budget that calls for spending more than * of the forecasted Adjusted Gross
Sales for the U.S. and Canada (“AGS”) during the period from Launch through the end of the next full calendar year after the year of the Launch (“U.S. First Year”). For purposes of this Amendment and the calculations herein,
forecasted AGS for U.S. First Year is set at * as approved by the NAJMC pursuant to Section 3(a) above. For avoidance of doubt, this provision does not affect the marketing spending limits set forth in paragraph 3(a) for subsequent years; nor does
it commit either party to agree to waive the caps in future years. Trimeris shall be fully responsible for its 50% pro rata share of all marketing and promotion expenses actually incurred during the U.S. First Year, except for the amount in excess
of * of forecasted AGS (the “Additional 2004 Marketing Expense”) up to a maximum of the budget established by the NAJMC for total shared Marketing and Promotion Expenses for the U.S. First Year, which budget will include actual 

 expenses for 2003 and which budget is expected to be established by the end of the first quarter of 2004.
Roche shall pay and be responsible for all of the Additional 2004 Marketing Expense. Trimeris shall be responsible for repaying 50% of the Additional 2004 Marketing Expenses (the “Trimeris Deferred Expenses”) according to the provisions of
paragraph 3(f) below. 
  

	 	3.	Paragraph 3(f) shall be added to Appendix D as follows: 

  
 Trimeris shall repay the Trimeris Deferred Expenses in accordance with the provisions of this paragraph. Repayment of the Trimeris Deferred Expenses shall
be triggered by the attainment of certain cumulative AGS milestones as set forth in the table below: 
  

							
	 (A)

	 	 (B)

	 	 (C)

	 	 (D)

	 Cumulative AGS for 2003-
 2007
 (USD millions)

	 	 Percentage
 of Trimeris
 Deferred
 Expenses to be
 Recovered
 Through Profit
 or Loss
 Calculation

	 	 Recovery Period
 Beginning *

	 	 Recovery Period for Remaining Balance,
Beginning Upon Achievement of
*Cumulative AGS

	 *
	 	*	 	 	 	*
	 *
	 	*	 	*	 	*
	 *
	 	*	 	*	 	*
	 *
	 	*	 	*	 	 

  
 Trimeris shall begin
to be charged additional amounts in the quarterly Profit or Loss Calculation Schedule (as set forth in Appendix B) to recover a portion of the Trimeris Deferred Expenses as specified in column B over the time period specified in column C, based upon
the cumulative AGS achieved during the time period from 2003 through 2007 specified in column A. Trimeris shall begin repaying the remaining balance due, if any, of the Trimeris Deferred Expenses (through quarterly Profit or Loss Calculation
Schedule adjustments) on the first day of the quarter after the quarter during which cumulative AGS first exceed*, or beginning on January 1, *, whichever is later. 
  
 The following example is provided for illustration and clarification. Assume that the Trimeris Deferred Expenses are in the
amount of * . If the cumulative AGS for 2003 through 2007 are equal to or greater than *, then Trimeris must repay the full amount of the Trimeris Deferred Expenses beginning on January 1, *, by 
  

 - 2 - 

 making eight (8) quarterly Profit or Loss Calculation Schedule adjustments of * over two (2) years. If
the cumulative AGS for 2003 through 2007 are equal to or greater than *but less than * , then Trimeris must repay * of the Trimeris Deferred Expenses beginning on January 1, *, by making eight (8) quarterly Profit or Loss Calculation Schedule
adjustments of * over two (2) years, and repaying the balance by making four (4) quarterly Profit or Loss Calculation Schedule adjustments of * over one (1) year beginning in the quarter after cumulative AGS exceed * . If the cumulative AGS for 2003
through 2007 are equal to or greater than * but less than *, then Trimeris must repay * of the Trimeris Deferred Expenses beginning on January 1, *, by making eight (8) quarterly Profit or Loss Calculation Schedule adjustments of * over two (2)
years, and repaying the balance by making eight (8) quarterly Profit or Loss Calculation Schedule adjustments of * over two (2) years beginning in the quarter after cumulative AGS exceed * . Finally, if the cumulative AGS for 2003 through 2007 are
less than * , then Trimeris must repay *of the Trimeris Deferred Expenses by making twelve (12) quarterly Profit or Loss Calculation Schedule adjustments of * over * years beginning in the quarter after cumulative AGS first exceed * . 
  

	 	4.	Paragraph 3(g) shall be added to Appendix D as follows: 

  
 At Roche’s option, Roche may accept repayment of Trimeris Deferred Expenses owed in the form of services rendered by Trimeris or as an offset against
any payments due and owing to Trimeris. 
  

	 	5.	Paragraph 3(h) shall be added to Appendix D as follows: 

  
 Upon expiration of this Agreement or termination by Roche for cause pursuant to Article 9 of the Agreement, the full amount of any portion of the Trimeris
Deferred Expenses still due and owing shall become due and payable in quarterly recovery payments over the following three-year period (“Accelerated Repayment Period”) or pursuant to one of the repayment schedules outlined in paragraph 2
above if such payments are already ongoing and would result in full repayment in less than three years. The first payment pursuant to an Accelerated Repayment Period is due on the later of the first day of the first full quarter after the
termination/expiration date or thirty (30) days after the termination/expiration date. If the Agreement is terminated by Trimeris for cause, the balance of the Trimeris Deferred Expenses shall be offset against any amounts owed by Roche to Trimeris.
Any remaining balance still owed to Roche shall then be repaid according to a schedule to be agreed upon by the parties. 
  

	 	6.	Entire Agreement. This Amendment, along with the Agreement previously executed by the Parties, shall constitute the entire agreement between the Parties with respect to the
subject matter of the Agreement. All other terms of the Agreement shall remain in full force and effect. To the extent that there are any inconsistencies between the terms of the Agreement and the terms of this Amendment, the terms of this Amendment
shall prevail in effect. 

  

 - 3 - 

 REST OF PAGE INTENTIONALY LEFT BLANK 
  

 - 4 - 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of the day and year first
above written. 
  

							
	TRIMERIS, INC.	 	HOFFMANN-LA ROCHE INC.
				
	By:	 	 /s/ Dani Bolognesi

	 	By:	 	 /s/ Dennis E. Burns

	 	 	Dani P.Bolognesi, Ph.D.	 	 	 	Dennis Burns
	 	 	Chief Executive Officer	 	 	 	Vice President
	 	 	 	 	 	 	Global Head of Business Development
			
	 	 	 	 	F. HOFFMANN-LA ROCHE LTD
				
	 	 	 	 	By:	 	 /s/ Rudolf Schaffner

	 	 	 	 	Name:	 	Rudolf Schaffner
	 	 	 	 	 	 	Global Head Legal Licensing
				
	 	 	 	 	By:	 	 /s/ Nigel Sheail

	 	 	 	 	Name:	 	Nigel Sheail
	 	 	 	 	Title:	 	Global Head of Acquisitions & Strategic Alliances

  

 - 5 -First Amendment to the Research Agreement

 Exhibit 10.30 
  
 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Commission. The omitted portions,
marked by “*”, have been separately filed with the Commission. 
  
 FIRST AMENDMENT TO THE RESEARCH AGREEMENT 
  
 This
AMENDMENT TO THE RESEARCH AGREEMENT (“Amendment”) is executed to be effective this 13th day of November
2003, by and between Trimeris, Inc. (“Trimeris”), and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively, “Roche”). 
  
 WHEREAS, Trimeris and Roche have previously entered into a Research Agreement (including its Appendices) dated effective as of the 1st day of January, 2000 by and between Trimeris and Roche (the “Agreement”), which sets forth the Parties rights,
duties and obligations under the Agreement; and 
  
 WHEREAS,
Trimeris and Roche desire to amend the Agreement to extend the term of the Joint Research Plan; and 
  
 WHEREAS, Section 13.7 of the Agreement permits the Parties to amend the Agreement to provide for changes or modifications of the Agreement mutually
desired by Trimeris and Roche. 
  
 NOW, THEREFORE, in
consideration for the foregoing promises and for good and valuable consideration, the receipt and sufficiency which is hereby acknowledged, the Parties hereby agree as follows: 
  

	 	1.	Section 1.34 shall be added as follows: “Third Party Costs” shall mean all costs paid by either Trimeris or Roche to any person or entity other than Trimeris or Roche or
their Affiliates pursuant to the Joint Research Plan for the Extended Term. 

  

	 	2.	Section 3.1 of the Agreement shall be amended to indicate that the Joint Research Committee shall consist of two (2) representatives from each of Roche and Trimeris.

  

	 	3.	Section 3.2 of the Agreement shall be amended to indicate that the Joint Research Committee shall meet at least quarterly. 

  

	 	4.	Section 3.3 of the Agreement shall be amended to indicate that in the event that the Joint Research Committee cannot reach consensus on a decision after referring the matter to the
persons with management responsibility for research at Roche and Trimeris respectively, then the matter will be referred to the Joint Steering Committee for resolution, such committee being defined in Sections 3.2 and 3.3 of the Development and
License Agreement dated July 1, 1999 by and between Trimeris, Inc., F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche Inc. 

	 	5.	Pursuant to Section 3.4, the Joint Research Plan for the Extended Term, along with the 2003 Budget for the 2003 Joint Research Plan activities including FTE and Third Party Costs
therefor, shall be attached as Appendix E to the Agreement. For 2003, Roche will pay Trimeris for its share of FTE and Third Party Costs (a) an estimated total of * for FTE costs and (b) an estimated total of * for Third Party Costs,
to be adjusted based on a reconciliation of actual expenditures as specified in Paragraph 6 of this Amendment below. The 2003 Budget payment from Roche to Trimeris will be in two installments: (a) * will be paid to Trimeris within 10 business
days after execution of this Agreement; and (b) the balance of the FTE and Third Party Costs owed by Roche will be paid to Trimeris by no later than March 31, 2004 based upon the reconciliation of actual expenses incurred. 

 

	 	6.	Section 3.5 of the Agreement shall be amended by replacing the original section as follows. 

  
 The purpose of the Joint Research Plan is to identify and approve a Drug Candidate for pre-clinical and clinical
development. The Joint Research Plan will avoid unnecessary duplication of work, responsibilities, and resources by the Parties and maximize utilization of the expertise of the Parties. A primary goal of the Joint Research Plan will be the equal
allocation of responsibilities, costs, and contributions between the Parties when measured in the aggregate. The Parties shall share Third Party Costs and FTE costs equally (split 50/50), for implementing the Joint Research Plan in accordance with
the work plan and assignment of responsibilities between the Parties as proposed by the Joint Research Committee in the Joint Research Plan approved by both Parties. In this regard, the Parties will contribute their share of the Joint Research Plan
in terms of employee resources, as personnel resources and expertise permits, and, if necessary, a monetary payment by one Party to the other Party to cover personnel expenses and Third Party Costs incurred by the other Party which exceed 50%. The
Parties will agree on a reconciliation of actual Third Party Costs and FTE costs incurred under the Joint Research Plan on a quarterly basis within 30 days of the end of a quarter. Within 30 days of the end of a calendar year, the Parties will agree
on a reconciliation of actual Third Party Costs and FTE costs incurred for the year, and payment will be made by the appropriate Party to the other Party within 30 days of the final reconciliation. The equal sharing of the costs of the Joint
Research Plan shall begin 01 January 2003 and extend to the termination of the Joint Research Plan. For the Extended Term, beginning 01 January 2003, the FTE rate under the Joint Research Plan is *, fully burdened, and shall be adjusted
annually to be consistent with the then current FTE rate determined by the Joint Steering Committee pursuant to Section 3 of the Development and License Agreement dated July 1, 1999 by and between Trimeris, Inc., F. Hoffmann-La Roche, Ltd. and
Hoffmann-La Roche Inc. From time to time, the Joint Research Committee may agree: (a) upon further research activities to be undertaken by the Parties including the scope and procedures for such research and responsibilities of each Party with
respect to such research; and (b) update and amend the Joint Research Plan in writing to reflect such further research activities subject to the approval of both Parties. The Joint Research Committee (JRC) shall also 

  

 - 2 - 

 
establish a budget for FTE costs and Third Party Costs on an annual basis, to be ratified by the JRC and agreed in writing by both Parties within sixty (60)
days after the beginning of each calendar year of the Extended Term. Each budget so approved will be attached to Appendix E of the Agreement as part of the Agreement. 
  

	 	7.	Section 3.6 shall be amended to indicate that the period of the Joint Research Plan shall be extended for a term of three (3) years, the extended term beginning on 01 January 2003
and ending on 31 December 2005 (“Extended Term”). With regard to further extensions of the Extended Term of the Joint Research Plan, Section 3.6 is hereby amended to indicate that the term of the Joint Research Plan, and the research
efforts to be undertaken pursuant thereto, shall renew for additional one year periods subject to joint Agreement by both Parties and approval by the JRC, such approval to be made at least ninety (90) days prior to the expiration of any Extended
Term or extension thereof. With regard to termination of the Joint Research Plan, the sentence in Section 3.6 reciting “In addition, the Joint Research Plan may be terminated at any time by mutual agreement of the Parties”, shall be
amended as follows. “In addition, the Joint Research Plan may be terminated at any time by mutual agreement of the Parties prior to November 01, 2004. Effective November 01, 2004, either Party may terminate the Joint Research Plan
by giving the other Party written notice of the intent to terminate at least sixty (60) days in advance of the termination date. Both Parties shall be liable for all Third Party Costs otherwise properly incurred pursuant to the Joint Research Plan,
or Third Party Costs under the Joint Research Plan which have been committed to incur and which cannot be mitigated, as of the termination date. Such Third Party Costs shall be reconciled as actual Third Party Costs according to the process for
reconciliation provided in amended Section 3.5 of the Agreement.” 

  

	 	8.	Section 2.4 of the Research Agreement defines certain rights of the Parties to sublicense Joint Research Patents outside the Field. By its terms such sublicense rights are limited
to Joint Research Patents for uses of Drug Candidates which will not be developed by the Parties in the Field. As such, the Parties note that section 2.4 does not provide guidance as to the Parties’ respective rights with regard to Joint
Research Patent rights which cover inventions apart from Drug Candidates and their uses such as process, formulation or other technology which may have application outside the Field (such rights hereinafter referred to as “Non-Drug Candidate
Patent Rights). Accordingly, the Parties amend Section 2.4 by adding the following at the end thereof: 

  
 “Within Joint Research Patents, any Non-Drug Candidate Patent Rights which cover inventions made solely by employees or agents of one of the Parties
shall be owned by that Party and shall be freely licensable by that Party outside of the Field. Within Joint Research Patents, any Non-Drug Candidate Patent Rights which cover inventions made jointly by employees or agents of both Parties shall be
jointly owned by both Parties and shall be freely licensable by either Party outside of the Field; provided that the Party proposing such license shall request 

  

 - 3 - 

 
the approval of the other Party, and if approved, the Parties shall agree to an equitable sharing of revenue from any such license prior to its conclusion,
the basis for reaching such agreement as set forth in the Research Agreement under this Section 2.4. “ 
  
 The foregoing amendment to section 2.4 shall apply nunc pro tunc as of the effective date of the Research Agreement and continue through any
Extended Term thereof. 
  

	 	9.	Entire Agreement. This Amendment, along with the Agreement previously executed by the Parties, shall constitute the entire agreement between the Parties with respect to the
subject matter of the Agreement. All other terms of the Agreement shall remain in full force and effect. To the extent that there is any inconsistencies between the terms of the Agreement and the terms of this Amendment, the terms of this Amendment
shall prevail in effect. 

  
 REST OF PAGE
INTENTIONALY LEFT BLANK 
  

 - 4 - 

 IN WITNESS WHEREOF, the Parties have executed this Amendment to be effective as of the day and year first
above written. 
  

							
	TRIMERIS, INC.	 	HOFFMANN-LA ROCHE INC.
				
	 By:
	 	 /s/    DANI P. BOLOGNESI

	 	 By:
	 	 /s/    LEE E. BABISS

	 	 	 Dani P. Bolognesi, Ph.D.
	 	 Name:
	 	 Lee E. Babiss, Ph.D.

	 	 	 Chief Executive Officer
	 	 Title:
	 	 Vice President of Pre-Clinical

	 	 	 	 	 	 	 Research and Development

  

			
	F. HOFFMANN-LA ROCHE LTD.
		
	 By:
	 	 /s/    BRAD BOLZON

	 Name:
	 	 Brad Bolzon, Ph.D.

	 Title:
	 	 Executive Vice President
 Business Development
 Licensing and Alliances

  

			
	F. HOFFMANN-LA ROCHE LTD.
		
	 By:
	 	 /s/    STEFAN ARNOLD

	 Name:
	 	 Stefan Arnold

	 Title:
	 	 Global Licensing Attorney

  

 - 5 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]